Stoke Therapeutics (STOK) Q2 2026 earnings review
Clinical Execution on Track, But Cash Burn is Accelerating
Stoke is executing its clinical plan flawlessly, successfully completing the critical 162-patient enrollment for its Phase 3 EMPEROR study in Dravet syndrome. However, this progress comes at a steep price. Operating expenses are accelerating dramatically, with R&D surging 91% YoY as the company funds the trial and prepares for a potential 2028 commercial launch. To maintain its "funded into 2028" narrative, management has quietly tapped its ATM facility for over $146 million in the last six months ($65.7 million post-Q2 alone). While the clinical timeline is de-risked, investors are enduring steady dilution ahead of the massive Q3 2027 binary data readout.
🐂 Bull Case
Enrolling 162 patients in the Phase 3 EMPEROR study is complete. The rapid pace of enrollment validates the high unmet medical need and keeps the critical Q3 2027 data readout locked in.
By initiating a rolling NDA in Q1 2027 before the final Phase 3 data is available, Stoke can front-load the FDA review process, significantly shortening the time to market if the Q3 2027 data is positive.
🐻 Bear Case
Despite boasting a strong cash runway, the company is quietly diluting shareholders to fund accelerating R&D and SG&A costs, raising over $146M via ATM facilities recently to keep the balance sheet above $400M.
The entire valuation of the company rests on the Q3 2027 Phase 3 readout. If the primary endpoint (major motor seizure frequency at week 28) misses, there is virtually no backup pipeline mature enough to support the current valuation.
⚖️ Verdict: ⚪
Neutral. The company is hitting every clinical milestone on time, which is rare in biotech. However, the accelerating cash burn and continuous ATM usage mean investors are paying a steep ongoing price to hold this stock into the 2027 data readout.
Key Themes
EMPEROR Study Hits Major Milestone
Stoke successfully completed enrollment of the targeted 162 patients for its pivotal Phase 3 EMPEROR study across the US, UK, and Japan. With approximately 60 patients already past Week 28, the clinical timeline is stable. The Q3 2027 data readout from this cohort will serve as the final piece of clinical data required to complete the rolling NDA submission.
Cash Burn Contradicts 'Runway' Narrative
Management claims the current $420M balance funds operations into early 2028. However, Q2 net loss accelerated to $61.6M. Annualizing this burn rate puts the company at ~$250M in annual cash usage. Without the unannounced, continuous ATM share sales ($80.7M in Q1, $65.7M post-Q2), the 'runway to 2028' would be in severe jeopardy. Investors should monitor this stealth dilution closely.
Regulatory De-risking via Rolling NDA
The FDA regulatory strategy is accelerating. With a pre-NDA meeting scheduled for H2 2026, Stoke plans to begin its rolling U.S. NDA submission in Q1 2027. This allows the FDA to review CMC (manufacturing) and non-clinical data early, leaving only the Phase 3 clinical data to be submitted in Q3 2027. This drastically shortens the ultimate approval timeline.
Pipeline Expansion: RNA Tech Targeting ADOA
While heavily dependent on Dravet syndrome, Stoke is attempting to validate its proprietary RNA platform in a second indication. The Phase 1 OSPREY study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) has completed dosing its first sentinel cohort with no severe safety events. H1 2027 data from this trial will be a critical catalyst to prove the company is more than a single-asset entity.
Lingering Safety Scrutiny: CSF Protein
While not explicitly addressed in the Q2 release, prior quarters highlighted that ~94% of patients in long-term studies experienced elevated cerebrospinal fluid (CSF) protein. While management has previously stated there are no serious clinical manifestations, this abnormal lab finding will undoubtedly be a major focal point for the FDA during the upcoming pre-NDA meeting and safety reviews.
Other KPIs
Stable. The reported cash balance on June 30 was $354.3M, but the company immediately raised $65.7M via ATM sales post-quarter to bolster the balance sheet to $420M. This compares to $411.0M in Q1 2026, showing that the company is effectively raising exactly enough equity to offset its accelerating burn rate quarter-over-quarter.
Accelerating dramatically. Up 91% from $25.9M in the prior year quarter. Driven entirely by the rapid enrollment of the Phase 3 EMPEROR study and manufacturing preparations for the rolling NDA. Expect these elevated levels to persist until the trial completes its 52-week dosing regimen.
Decelerating. Down from $13.8M YoY. This revenue is strictly from satisfying contractual obligations with partners Acadia and Biogen. It is non-commercial, highly irregular, and should not be factored into the core valuation of the business.
Guidance
Stable. The primary value-inflection point remains locked in. With enrollment complete, the timeline is now strictly governed by the 52-week treatment period.
Stable. The pre-NDA meeting in H2 2026 will finalize the agreement to submit non-clinical and manufacturing data in Q1, accelerating the overall pathway to market.
Stable. Dose escalation is continuing for STK-002. This will be the first major pipeline diversification data point before the pivotal Dravet data later in the year.
Key Questions
Expense Trajectory Post-Enrollment
With the 162-patient Phase 3 EMPEROR enrollment now complete, will we see a stabilization in R&D expenses, or will manufacturing and CMC costs for the rolling NDA keep pushing quarterly burn rates higher?
Pre-NDA Meeting Focus
Heading into the H2 2026 pre-NDA meeting with the FDA, what specific early data modules (CMC, animal toxicology) are fully prepared for the planned Q1 2027 rolling submission?
CSF Protein Elevation Scrutiny
Given that ~94% of patients in prior long-term studies showed elevated CSF protein, how is the company preparing to defend this safety signal to the FDA during the upcoming regulatory meetings?